Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance.

Fabrizio CalapaiCarmen MannucciMariaconcetta CurròLuigi Cardia Emanuela Esposito Gioacchino Calapai Ilaria Ammendolia

Published in: Pharmaceuticals (Basel, Switzerland) (2024)

The post-marketing safety profile of evolocumab emerging from an analysis of the EudraVigilance data system indicates it is sufficiently safe but suggests the necessity for caution when it is prescribed to hyperlipidemic patients affected by heart diseases.

Keyphrases

end stage renal disease
electronic health record
newly diagnosed
chronic kidney disease
heart failure
big data
peritoneal dialysis
emergency department
patient reported outcomes